Verdegaal, Els M. E.
de Miranda, Noel F. C. C.
Visser, Marten
Harryvan, Tom
van Buuren, Marit M.
Andersen, Rikke S.
Hadrup, Sine R.
van der Minne, Caroline E.
Schotte, Remko
Spits, Hergen
Haanen, John B. A. G.
Kapiteijn, Ellen H. W.
Schumacher, Ton N.
van der Burg, Sjoerd H.
Article History
Received: 18 February 2016
Accepted: 21 June 2016
First Online: 27 June 2016
Competing interests
: AIMM Therapeutics holds IP to immortalize human B cells, and AIMM Therapeutics/ The Netherlands Cancer Institute hold IP for the use of immortalized human B cells to identify T cell epitopes. H.S. and R.S. are employees and stockholders of AIMM Therapeutics. T.N.S. is a scientific advisor and stockholder of AIMM Therapeutics.